Caris Life Sciences saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 89 to 93.
Here Are 3 Keys For Successful Stock Investing
This proprietary rating measures market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks matches up against the rest of the market.
Over 100 years of market history shows that the best-performing stocks typically have an RS Rating north of 80 in the early stages of their moves.
Caris Life Sciences is now considered extended and out of buy range after clearing a 30.70 buy point in a first-stage ipo base. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Caris Life Sciences reported 0% earnings growth in its most recent report. Sales rose 81%.
Caris Life Sciences holds the No. 9 rank among its peers in the Medical-Research Equipment/Services industry group. Medpace Holdings, IQVIA Holdings and Tempus AI are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
